Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.
Location: United States, Massachusetts, Watertown
Employees: 11-50
Total raised: $81M
Investors 1
| Date | Name | Website |
| 05.09.2022 | Arkin Hold... | arkinholdi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.12.2022 | Series A | $81M | - |
Mentions in press and media 5
| Date | Title | Description |
| 17.12.2022 | 4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A | Company’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) molecules |
| 07.12.2022 | Entact Bio Launch with $81M Series A to Develop Precision Medicines for Targeted Protein Enhancement | Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio Partners |
| 06.12.2022 | Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement | Entact Bio, the company pioneering the development of precision medicines that enhance the function of key proteins, today announced it has raised $81 million in Series A financing to advance its proprietary Encompass™ platform for developi... |
| - | Entact Bio | “Creating new medicines by enhancing protein function.” |
| - | Entact Bio | “Entact Bio | Creating new medicines by enhancing protein function” |